Market Outlook - Digital Health
- Global equity funding climbed to $7.4B in Q1’26, a 25% increase quarter-over-quarter from the Q4’25 total of $5.9B, and the highest quarterly total since Q2’22.
- The average global deal size increased from $20.2M in 2025 to $29.6M in Q1’26, ultimately spurred by larger investments in later-stage rounds, with mega-rounds ($100M+) capturing a record 60% of all capital across just nineteen financings.
- Capital is concentrating around AI’s move into clinical and commercial decision-making, with big pharma partnering directly with discovery platforms rather than acquiring them outright, while buyers elsewhere in the market are increasingly pricing deals on commercial traction rather than regulatory clearance alone.
- The U.S. market share of deals dropped from 56% in Q4’25 to 47% in Q1’26, signaling that global investors are spreading capital more evenly as Europe gains momentum in digital health investment.
- Among the quarter’s top fundraising deals were Earendil Labs’ $787M private equity round, backed by Hillhouse Investment and DST Global, and Whoop’s $575M Series G at a $10.1B valuation, led by Collaborative Fund.
- Digital health M&A activity surged from Q4’25 to Q1’26, with M&A exits climbing from 38 to 56. Abbott’s $23B acquisition of Exact Sciences led the quarter, alongside DeepHealth’s $269M purchase of Gleamer.
Sources: CB Insights
Subsector Spotlight: Medical Imaging AI
- The global AI in medical imaging market was valued at approximately $1.8 billion in 2025 and is forecast to reach $20.2 billion by 2033 at a ~35.1% CAGR, reflecting accelerating adoption across hospitals and diagnostic centers worldwide.
- Investment and deployment continue to accelerate as health systems look to improve diagnostic accuracy, reduce radiologist workload, and streamline imaging workflows. In the U.S. alone, the AI in medical imaging market is estimated at $697 million in 2025 and is projected to grow to $2.9 billion by 2030 at a 33.2% CAGR, fueled by rising demand for AI-enabled disease detection and patient monitoring tools.
- Adoption is diversifying across imaging modalities (CT, MRI, X-ray, ultrasound) and clinical applications (neurology, oncology, cardiology), with deep learning leading the technology approach and North America holding the largest regional share.
Sources: Grand View Research, CapIQ
Highly regulated market requiring FDA clearance (U.S.), CE marking (EU), and country-specific regulatory approvals prior to commercialization
Fragmented vendor landscape with hundreds of point solutions focused on specific anatomies, modalities, or clinical use cases, alongside larger imaging OEMs and workflow platform providers
Complex integration requirements, as solutions must interoperate seamlessly with PACS, RIS, EHR systems, and hospital IT infrastructure
Continued reliance on clinical validation, radiologist trust, and established distribution partnerships, despite growing automation and AI-driven workflow capabilities
Public Comparables
Source: Capital IQ as of 06/24/26
*: denotes statistic outliers
NM: denotes not meaningful
Indexed Stock Performance
Source: Capital IQ as of 06/24/26
(1) Healthcare IT/Analytics: IQV, VEEV, DOCS, HCAT, EXL
(2) Care Coordination Software: EVH, AVAH, ALHC, DCGO, TDOC, CCLD, PHR, MDRX
(3) RPM: HON, MDT, RMD, DXCM, MASI, IRTC, DCGO
(4) RCM: WAY, PHR, TBRG, HCAT, RCMT, CCLD
(5) Telemedicine: DOCS, HIMS, LFST, TDOC, TALK, HCAT, LFMD
(6) Prescription Tech: PRVA, GDRX, OMCL, RCMT, YI, CCLD, MDRX
(7) EHR Software: ORCL, PHR, TBRG, OPRX, CCLD, VHI,
(8) HealthTech Devices: BSX, EW, ZBH, DXCM, LUMN, IART, IRTC, LMAT, ANGO, OM, MDT, SYK, PHIA
Select Digital Health M&A Transactions
Sources: PitchBook; Capital IQ; CB Insights
Global Digital Health Equity Funding & Deal Activity by Quarter
Source: CB Insights
HPC Overview
- Hyde Park Capital is one of the most active boutique investment banks in the country managing sell-side M&A engagements in the Digital Health sector
- Advised on 300+ transactions and has been a consistent leader in providing independent and unbiased strategic counsel and advisory services to global sellers and buyers of middle-market firms
- Diverse team with extensive execution experience across all areas of Healthcare
- Bulge bracket capabilities with a boutique touch
Healthcare Coverage
Digital Health
Managed Care
Life Science Tools / Diagnostics
Medical Devices
Pharma Services
Healthcare Providers
Pharmaceuticals/Biotechnology
With a Focus on Digital Health
Revenue Cycle Management
Virtual Care & Telehealth
HealthTech Devices
EHR Software
Healthcare IT / Analytics
Prescription Technology
Clinical Trial Technology
HEALTHCARE INVESTMENT BANKING TRANSACTIONS
Recent Healthcare Transactions
Check out our track record of previous Healthcare Transactions.
Loading transactions...